WO2008140598A3 - Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci - Google Patents
Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci Download PDFInfo
- Publication number
- WO2008140598A3 WO2008140598A3 PCT/US2007/086335 US2007086335W WO2008140598A3 WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3 US 2007086335 W US2007086335 W US 2007086335W WO 2008140598 A3 WO2008140598 A3 WO 2008140598A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mycobacterium strains
- mycobacteria
- pharmaceutic
- methods
- genetically modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Cette invention concerne des souches de Mycobacterium génétiquement modifiées qui sont utiles comme agents immunothérapeutiques anti-cancers. Les souches de Mycobacterium génétiquement modifiées présentent de préférence au moins une modification génétique conduisant à une adhérence tissulaire accrue, qui peut être combinée avec des modifications génétiques qui augmentent l'immunopuissance et conduisent à une production d'adjuvants. L'invention concerne également des compositions et des procédés pour le développement desdites souches de Mycobacterium, et des compositions pharmaceutiques et des procédés pour l'utilisation desdites souches de Mycobacterium comme agents thérapeutiques anti-cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86845006P | 2006-12-04 | 2006-12-04 | |
US60/868,450 | 2006-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008140598A2 WO2008140598A2 (fr) | 2008-11-20 |
WO2008140598A3 true WO2008140598A3 (fr) | 2016-06-09 |
Family
ID=40002815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/086335 WO2008140598A2 (fr) | 2006-12-04 | 2007-12-04 | Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008140598A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US9139809B2 (en) * | 2009-01-08 | 2015-09-22 | Albert Einstein College Of Medicine Of Yeshiva University | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
US12359209B2 (en) | 2018-04-17 | 2025-07-15 | The Johns Hopkins Unversity | Recombinant therapeutic interventions for cancer |
WO2022203308A1 (fr) * | 2021-03-22 | 2022-09-29 | 클립스비엔씨 주식회사 | Nouvelle souche recombinée de mycobacterium smegmatis et son utilisation |
WO2023150848A1 (fr) * | 2022-02-11 | 2023-08-17 | Instituto Butantan | Compositions comprenant des souches de mycobacterium recombinantes, leurs utilisations et méthodes pour la prévention et/ou le traitement de cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050220811A1 (en) * | 2002-04-05 | 2005-10-06 | Stewart Cole | Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti |
EP1882741A1 (fr) * | 2006-07-25 | 2008-01-30 | Institut Pasteur | Souche de Mycobacterium exprimant une proteine FAP sous le contrôle d'un promoteur qui est actif en conditions d' hypoxie et ses applications pour la thérapie du cancer |
-
2007
- 2007-12-04 WO PCT/US2007/086335 patent/WO2008140598A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050220811A1 (en) * | 2002-04-05 | 2005-10-06 | Stewart Cole | Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti |
EP1882741A1 (fr) * | 2006-07-25 | 2008-01-30 | Institut Pasteur | Souche de Mycobacterium exprimant une proteine FAP sous le contrôle d'un promoteur qui est actif en conditions d' hypoxie et ses applications pour la thérapie du cancer |
Non-Patent Citations (5)
Title |
---|
LEWIS ET AL.: "Deletion of RD1 from Mycobacterium tuberculosis Mimics Bacille Calmette-Guerin Attenuation.", JOURNAL OF INFECTIOUS DISEASES, vol. 187, no. 1, 2003, pages 117 - 23, XP002987276, DOI: doi:10.1086/345862 * |
MIYAMOTO ET AL.: "Aggregation of mycobacteria caused by disruption of fibronectin-attachment protein-encoding gene .", FEMS MICROBIOLOGY LETTERS, vol. 236, no. 2, 2004, pages 227 - 234 * |
SECOTT ET AL.: "Fibronectin Attachment Protein Is Necessary for Efficient Attachment and Invasion of Epithelial Cells by Mycobacterium avium subsp. paratuberculosis.", INFECTION AND IMMUNITY, vol. 70, no. 5, May 2002 (2002-05-01), pages 2670 - 2675 * |
ZHAO ET AL.: "Characterization of the Fibronectin Binding Motif for a Unique Mycobacterial Fibronectin Attachment Protein, FAP.", J. BIOL CHEM, vol. 274, no. 8, 19 February 1999 (1999-02-19), pages 4521 - 4526 * |
ZHAO ET AL.: "ROLE OF A BACILLUS CALMETTE-GUERIN FIBRONECTIN ATTACHMENT PROTEIN IN BCG-INDUCED ANTITUMOR ACTIVITY.", INT. J. CANCER, vol. 86, no. 1, 2000, pages 83 - 88, XP002401487, DOI: doi:10.1002/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R * |
Also Published As
Publication number | Publication date |
---|---|
WO2008140598A2 (fr) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010144344A3 (fr) | Peptides spécifiques du récepteur de la mélanocortine | |
EP3219815A3 (fr) | Procédés et compositions de production de squalène au moyen de la levure | |
WO2008140598A3 (fr) | Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci | |
WO2010078457A3 (fr) | Procédé de fabrication d'isoprène et d'un co-produit | |
MX2010004244A (es) | Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk). | |
EP3444352A3 (fr) | Production d'un vaccin recombinant dans e. coli par conjugaison enzymatique | |
WO2007113841A3 (fr) | Nouveaux aminoglycosides et leurs utilisations dans le traitement de troubles génétiques | |
EP2698412A3 (fr) | Composé contenant un mésogène | |
WO2006120208A8 (fr) | Procedes de preparation de derives de benzylbenzene a substitution glucopyranosyl et intermediaires obtenus selon ces procedes | |
EP2537857A3 (fr) | Formes mutantes de streptolysine O | |
IL200407A0 (en) | Stable digestive enzyme compositions, methods of producing the same and uses thereof | |
WO2008005705A3 (fr) | Formulations à teneur métallique et procédés d'utilisation | |
WO2008049758A3 (fr) | Colorants pour dispersion, leur fabrication et leur utilisation | |
WO2007021937A3 (fr) | Derives heterocycliques insatures | |
WO2011008495A3 (fr) | Formulations d'arginase et procédés | |
WO2009135646A3 (fr) | Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle | |
WO2009042114A3 (fr) | Dérivés de phénazine et leurs utilisations | |
WO2008089397A3 (fr) | Marqueurs du cancer adrb2 | |
WO2008109142A3 (fr) | ARNpi ET UTILISATIONS CORRESPONDANTES | |
WO2009042809A8 (fr) | Compositions d'imatinib stables | |
WO2011140595A3 (fr) | Compositions immunostimulatrices et vaccinales | |
WO2011029547A3 (fr) | Dérivés d'isoxazolidine | |
WO2009007535A3 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
WO2010132112A3 (fr) | Compositions immunogènes contre la tuberculose | |
WO2012082483A3 (fr) | Lieurs multifonctionnels et procédés d'utilisation associés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07874337 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07874337 Country of ref document: EP Kind code of ref document: A2 |